Regor’s most advanced orally-administered CDK4/2 inhibitor in the clinic, RGT-419B, will be added to Roche’s pipeline. RGT-419B is a potent CDK4 inhibitor with increased activity on CDK2 ...

Cambridge, Massachusetts-based biotech Regor Therapeutics Group has agreed to sell its portfolio of CDK inhibitors for the treatment of breast cancer to Roche's Genentech for an upfront cash ...

In the same period Zolgensma grew 18% to $363 million. Regor Therapeutics Group has agreed to sell its portfolio of CDK inhibitors to Roche's Genentech for an upfront cash payment of $850 million.

The lead asset from Regor is called RGT-419B and it's currently ... this solution is critical for our success in blood safety in the U.S. as Roche can now offer the full package of nucleic acid ...

Roche ROG-0.57%decrease; red down pointing triangle confirmed its profit outlook for the year after its eye drug Vabysmo, multiple-sclerosis treatment Ocrevus and hemophilia injection Hemlibra ...

Roche doesn’t think so. “I think we don’t see anything that should be slowing Vabysmo momentum down,” Teresa Graham, CEO of Roche Pharmaceuticals, said during a press conference Wednesday ...

Roche CEO: not good to limit competition in this space Roche says not itself, but others affected by Catalent deal Swiss drugmaker joins US peer Lilly in voicing opposition Eli Lilly and advocacy ...

Swiss pharmaceutical giant Roche said Wednesday that it was increasing its capacity to produce diagnostic tests to detect mpox, amid a flare-up of the potentially deadly virus. "We've ramped up ...

Roche RHHBY announced an asset purchase agreement with clinical-stage biotechnology company Regor Therapeutics. Per the agreement, Roche’s Genentech will acquire Regor’s portfolio of next-generation ...

FRANKFURT (Reuters) -The CEO of pharmaceuticals giant Roche said authorities should block the takeover of contract drug manufacturer Catalent by Novo Nordisk's controlling shareholder, as it could ...